2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T4ad,Of 783 patients enrolled (mean [SD] age, 48.0 [15.5] years; 376 [48.0%] female), 393 received home-based phototherapy and 390 received office-based phototherapy, with 350 (44.7%) having skin phototype (SPT) I/II, 350 (44.7%) having SPT III/IV, and 83 (10.6%) having SPT V/VI. A total of 93 patients (11.9%) were receiving systemic treatment. At baseline, mean (SD) PGA was 2.7 (0.8) and DLQI was 12.2 (7.2). At week 12, 129 patients (32.8%) receiving home-based phototherapy and 100 patients (25.6%) receiving office-based phototherapy achieved clear/almost clear skin, and 206 (52.4%) and 131 (33.6%) achieved DLQI of 5 or lower, respectively. Home-based phototherapy was noninferior to office-based phototherapy for PGA and DLQI in the overall population and across all SPTs. Home-based phototherapy, compared to office-based phototherapy, was associated with better treatment adherence (202 patients [51.4%] vs 62 patients [15.9%]; P < .001), lower burden of indirect costs to patients, and more episodes of persistent erythema (466 of 7957 treatments [5.9%] vs 46 of 3934 treatments [1.2%]; P < .001). Both treatments were well tolerated with no discontinuations due to adverse events.31:Taa5,Office-based phototherapy is cost-effective for psoriasis but difficult to access. Home-based phototherapy is patient preferred but has limited clinical data, particularly in patients with darker skin. To compare the effectiveness of home- vs office-based narrowband UV-B phototherapy for psoriasis. The Light Treatment Effectiveness study was an investigator-initiated, pragmatic, open-label, parallel-group, multicenter, noninferiority randomized clinical trial embedded in routine care at 42 academic and private clinical dermatology practices in the US. Enrollment occurred from March 1, 2019, to December 4, 2023, with follow-up through June 2024. Participants were 12 years and older with plaque or guttate psoriasis who were candidates for home- and office-based phototherapy. Participants were randomized to receive a home narrowband UV-B machine with guided mode dosimetry or routine care with office-based narrowband UV-B for 12 weeks, followed by an additional 12-week observation period. The coprimary effectiveness outcomes were Physician Global Assessment (PGA) dichotomized as clear/almost clear skin (score of ≤1) at the end of the intervention period and Dermatology Life Quality Index (DLQI) score of 5 or lower (no to small effect on quality of life) at week 12. Of 783 patients enrolled (mean [SD] age, 48.0 [15.5] years; 376 [48.0%] female), 393 received home-based phototherapy and 390 received office-based phototherapy, with 350 (44.7%) having skin phototype (SPT) I/II, 350 (44.7%) having SPT III/IV, and 83 (10.6%) having SPT V/VI. A total of 93 patients (11.9%) were receiving systemic treatment. At baseline, mean (SD) PGA was 2.7 (0.8) and DLQI was 12.2 (7.2). At week 12, 129 patients (32.8%) receiving home-based phototherapy and 100 patients (25.6%) receiving office-based phototherapy achieved clear/almost clear skin, and 206 (52.4%) and 131 (33.6%) achieved DLQI of 5 or lower, respectively. Home-based phototherapy was noninferior to office-based phototherapy for PGA and DLQI in the overall population and across all SPTs. Home-based phototherapy, compared to office-based phototherapy, was associated with better treatment adherence (202 patients [51.4%] vs 62 patients [15.9%]; P < .001), lower burden of indirect costs to patients, and more episodes of persistent erythema (466 of 7957 treatments [5.9%] vs 46 of 3934 treatments [1.2%]; P < .001). Both treatments were well tolerated with no discontinuations due to adverse events. In this randomized clinical trial, home-based phototherapy was as effective as office-based phototherapy for plaque or guttate psoriasis in everyday clinical practice and had less burden to patients. ClinicalTrials.gov Identifier: NCT03726489.32:Te05,ImportanceOffice-based phototherapy is cost-effective for psoriasis but difficult to access. Home-based phototherapy is patient preferred but has limited clinical data, particularly in patients with darker skin.ObjectiveTo compare the effectiveness of home- vs office-based narrowband UV-B phototherapy for psoriasis.Design, Setting, and ParticipantsThe Light Treatment Effectiveness study was an investigator-initiated, pragmatic, open-label, parallel-group, multicenter, noninferiority randomized clinical trial embedded in routine care at 42 academic and private clinical dermatology practices in the US. Enrollment occurred from March 1, 2019, to December 4, 2023, with follow-up through June 2024. Participants were 12 years and older with plaque or guttate psoriasis who were candidates for home- and office-based phototherapy.InterventionsParticipants were randomized to receive a home narrowband UV-B machine with guided mode dosimetry or routine care with office-based narrowband UV-B for 12 weeks, followed by an additional 12-week observation period.Main Outcomes and MeasuresThe coprimary effectiveness outcomes were Physician Global Assessment (PGA) dichotomized as clear/almost clear skin (score of ≤1) at the end of the intervention period and Dermatology Life Quality Index (DLQI) score of 5 or lower (no to small effect on quality of life) at week 12.ResultsOf 783 patients enrolled (mean [SD] age, 48.0 [15.5] years; 376 [48.0%] male), 393 received home-based phototherapy and 390 received office-based phototherapy, with 350 (44.7%) having skin phototype (SPT) I/II, 350 (44.7%) having SPT III/IV, and 83 (10.6%) having SPT V/VI. A total of 93 patients (11.9%) were receiving systemic treatment. At baseline, mean (SD) PGA was 2.7 (0.8) and DLQI was 12.2 (7.2). At week 12, 129 patients (32.8%) receiving home-based phototherapy and 100 patients (25.6%) receiving office-based phototherapy achieved clear/almost clear skin, and 206 (52.4%) and 131 (33.6%) achieved DLQI of 5 or lower, respectively. Home-based phototherapy was noninferior to office-based phototherapy for PGA and DLQI in the overall population and across all SPTs. Home-based phototherapy, compared to office-based phototherapy, was associated with better treatment adherence (202 patients [51.4%] vs 62 patients [15.9%]; P &lt; .001), lower burden of indirect costs to patients, and more episodes of persistent erythema (466 of 7957 treatments [5.9%] vs 46 of 3934 treatments [1.2%]; P &lt; .001). Both treatments were well tolerated with no discontinuations due to adverse events.Conclusions and RelevanceIn this randomized clinical trial, home-based phototherapy was as effective as office-based phototherapy for plaque or guttate psoriasis in everyday clinical practice and had less burden to patients.Trial RegistrationClinicalTrials.gov Identifier: NCT0372648925:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Narrowband UV-B Phototherapy: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Narrowband UV-B Phototherapy (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Narrowband%20UV-B%20Phototherapy\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Narrowband UV-B Phototherapy\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Narrowband%20UV-B%20Phototherapy\"}]}}"}}]],["$","$L2f",null,{"title":"Narrowband UV-B Phototherapy: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Narrowband UV-B Phototherapy — concise summaries and practical next steps.","papers":[{"doi":"10.1001/jamadermatol.2024.3897","pmid":"39319513","title":"Home- vs Office-Based Narrowband UV-B Phototherapy for Patients With Psoriasis","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2024-09-25T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2024.3897","source_score":72,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2024-10-03","doi":"10.1001/jamadermatol.2024.3897","days":"30","issn":"2168-6068","rank":"5","field":"Clinical Medicine","score":"72","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2024.3897","title":"Home- vs Office-Based Narrowband UV-B Phototherapy for Patients With Psoriasis: The LITE Randomized Clinical Trial.","journal":"JAMA dermatology","methods":"","results":"$30","abstract":"$31","keywords":[],"pubmed_id":"39319513","conclusions":"","publication_date":"2024-09-25T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2024.3897","URL":"https://doi.org/10.1001/jamadermatol.2024.3897","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2823901/jamadermatology_gelfand_2024_oi_240047_1738096855.76769.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"1320","type":"journal-article","issue":"12","score":1,"title":["Home- vs Office-Based Narrowband UV-B Phototherapy for Patients With Psoriasis"],"author":[{"given":"Joel M.","family":"Gelfand","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia"},{"name":"Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, University of California, Los Angeles"}]},{"given":"Henry W.","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Henry Ford Health, Detroit, Michigan"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina"}]},{"given":"Sandra M.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Johnson Dermatology, Fort Smith, Arizona"}]},{"given":"W. C. Cole","family":"Claiborne","sequence":"additional","affiliation":[{"name":"MD Claiborne & Associates Dermatology, New Orleans, Louisiana"}]},{"given":"Robert E.","family":"Kalb","sequence":"additional","affiliation":[{"name":"Department of Dermatology, SUNY at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York"}]},{"given":"Jeannette","family":"Jakus","sequence":"additional","affiliation":[{"name":"Deparment of Dermatology, SUNY Downstate Health Sciences University, Brooklyn, New York"}]},{"given":"Aaron R.","family":"Mangold","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mayo Clinic, Scottsdale, Arizona"}]},{"given":"R. Hal","family":"Flowers","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Virginia Health System, Charlottesville"}]},{"given":"Tina","family":"Bhutani","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}]},{"given":"John R.","family":"Durkin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of New Mexico, Albuquerque"}]},{"given":"Jerry","family":"Bagel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York City, New York"}]},{"given":"Scott","family":"Fretzin","sequence":"additional","affiliation":[{"name":"Dawes Fretzin Dermatology Group, Indianapolis, Indiana"}]},{"given":"Michael P.","family":"Sheehan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Indiana University School of Medicine, Indianapolis"}]},{"given":"James","family":"Krell","sequence":"additional","affiliation":[{"name":"Total Dermatology, Birmingham, Alabama"}]},{"given":"Margo","family":"Reeder","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison"}]},{"given":"Jessica","family":"Kaffenberger","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus"}]},{"given":"Francisca","family":"Kartono","sequence":"additional","affiliation":[{"name":"MI Skin Center, Northville, Michigan"}]},{"given":"Junko","family":"Takeshita","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia"},{"name":"Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}]},{"given":"Alisha M.","family":"Bridges","sequence":"additional","affiliation":[{"name":"Patient advocate and LITE study stakeholder committee member, Atlanta, Georgia"}]},{"given":"Eric","family":"Fielding","sequence":"additional","affiliation":[{"name":"Patient advocate and LITE study stakeholder committee member, Melbourne, Florida"}]},{"given":"Umbereen S.","family":"Nehal","sequence":"additional","affiliation":[{"name":"MIT Sloan School of Management, Cambridge, Massachusetts"}]},{"given":"Kenneth L.","family":"Schaecher","sequence":"additional","affiliation":[{"name":"University of Utah Health Plans, Murray"}]},{"given":"Leah M.","family":"Howard","sequence":"additional","affiliation":[{"name":"National Psoriasis Foundation, Alexandria, Virginia"}]},{"given":"Guy S.","family":"Eakin","sequence":"additional","affiliation":[{"name":"National Psoriasis Foundation, Alexandria, Virginia"}]},{"given":"Suzette","family":"Báez","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia"}]},{"given":"Brooke E.","family":"Bishop","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia"}]},{"given":"Robert C.","family":"Fitzsimmons","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia"}]},{"given":"Maryte","family":"Papadopoulos","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia"}]},{"given":"William B.","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia"}]},{"given":"Kristin A.","family":"Linn","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}]},{"given":"Rebecca A.","family":"Hubbard","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Department of Biostatistics, Brown University School of Public Health, Providence, Rhode Island"}]},{"given":"Daniel B.","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia"}]},{"given":"Kristina","family":"Callis Duffin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Utah School of Medicine, Salt Lake City"}]}],"issued":{"date-parts":[[2024,12,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"160","created":{"date-time":"2024-09-25T12:20:21Z","timestamp":1727266821000,"date-parts":[[2024,9,25]]},"indexed":{"date-time":"2025-07-03T07:37:37Z","timestamp":1751528257530,"date-parts":[[2025,7,3]]},"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2823901"}},"subtitle":["The LITE Randomized Clinical Trial"],"deposited":{"date-time":"2025-01-29T16:26:25Z","timestamp":1738167985000,"date-parts":[[2025,1,29]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2024,12,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1016/j.jaad.2016.07.064","key":"doi240047r1","year":"2017","issue":"3","author":"Takeshita","volume":"76","first-page":"377","unstructured":null,"article-title":"Psoriasis and comorbid diseases: epidemiology.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.296.14.1735","key":"doi240047r2","year":"2006","issue":"14","author":"Gelfand","volume":"296","first-page":"1735","unstructured":null,"article-title":"Risk of myocardial infarction in patients with psoriasis.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2017.10.050","key":"doi240047r3","year":"2018","issue":"2","author":"Wan","volume":"78","first-page":"315","unstructured":null,"article-title":"Psoriasis and the risk of diabetes: a prospective population-based cohort study.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1038/jid.2011.365","key":"doi240047r4","year":"2012","issue":"3 pt 1","author":"Langan","volume":"132","first-page":"556","unstructured":null,"article-title":"Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41467-022-34323-4","key":"doi240047r5","year":"2022","issue":"1","author":"Patrick","volume":"13","first-page":"6565","unstructured":null,"article-title":"Shared genetic risk factors and causal association between psoriasis and coronary artery disease.","journal-title":"Nat Commun","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.2010.09941.x","key":"doi240047r6","year":"2010","issue":"3","author":"Abuabara","volume":"163","first-page":"586","unstructured":null,"article-title":"Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2017.07.841","key":"doi240047r7","year":"2018","issue":"1","author":"Noe","volume":"138","first-page":"228","unstructured":null,"article-title":"Objective measures of psoriasis severity predict mortality: a prospective population-based cohort study.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2019.08.011","key":"doi240047r8","year":"2021","issue":"2","author":"Semenov","volume":"85","first-page":"396","unstructured":null,"article-title":"Psoriasis and mortality in the United States: data from the National Health and Nutrition Examination Survey.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(20)32549-6","key":"doi240047r9","year":"2021","issue":"10281","author":"Griffiths","volume":"397","first-page":"1301","unstructured":null,"article-title":"Psoriasis.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2022.0364","key":"doi240047r10","year":"2022","issue":"5","author":"Pina Vegas","volume":"158","first-page":"513","unstructured":null,"article-title":"Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the French Health Insurance Database.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2012.06.035","key":"doi240047r11","year":"2013","issue":"1","author":"Yeung","volume":"68","first-page":"64","unstructured":null,"article-title":"Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41598-018-34293-y","key":"doi240047r12","year":"2018","issue":"1","author":"Lin","volume":"8","first-page":"16068","unstructured":null,"article-title":"Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence.","journal-title":"Sci Rep","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2018.0183","key":"doi240047r13","year":"2018","issue":"5","author":"Mason","volume":"154","first-page":"581","unstructured":null,"article-title":"Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.12788/cutis.0674","key":"doi240047r14","year":"2022","issue":"6","author":"Torosian","volume":"110","first-page":"E3","unstructured":null,"article-title":"Factors influencing patient preferences for phototherapy: a survey study.","journal-title":"Cutis","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2019.04.042","key":"doi240047r15","year":"2019","issue":"3","author":"Elmets","volume":"81","first-page":"775","unstructured":null,"article-title":"Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.18846","key":"doi240047r16","year":"2023","issue":"5","author":"Iversen","volume":"37","first-page":"1004","unstructured":null,"article-title":"Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: week 52 results from the STEPIn study.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2023.11.053","key":"doi240047r17","year":"2024","issue":"4","author":"Wang","volume":"90","first-page":"759","unstructured":null,"article-title":"Incidence and profile of skin cancers in patients following ultraviolet phototherapy without psoralens: a retrospective cohort study.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1468-3083.2012.04520.x","key":"doi240047r18","year":"2012","issue":null,"author":"Archier","volume":"26","first-page":"22","unstructured":null,"article-title":"Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1161/CIRCIMAGING.117.007394","key":"doi240047r19","year":"2018","issue":"6","author":"Mehta","volume":"11","first-page":null,"unstructured":null,"article-title":"Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial.","journal-title":"Circ Cardiovasc Imaging","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2019.05.080","key":"doi240047r20","year":"2019","issue":"4","author":"Noe","volume":"81","first-page":"923","unstructured":null,"article-title":"Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: a randomized controlled study.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/ijd.16677","key":"doi240047r21","year":"2023","issue":"8","author":"McCoy","volume":"62","first-page":"986","unstructured":null,"article-title":"Systematic review and estimated cost-efficacy of biologics compared with narrowband ultraviolet B light for the treatment of moderate to severe psoriasis and atopic dermatitis.","journal-title":"Int J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1038/d41573-024-00018-2","key":"doi240047r22","year":"2024","issue":"7","author":"Al-Horani","volume":"23","first-page":"492","unstructured":null,"article-title":"The pipeline and market for psoriasis drugs.","journal-title":"Nat Rev Drug Discov","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2020.04.095","key":"doi240047r23","year":"2021","issue":"2","author":"Torres","volume":"84","first-page":"479","unstructured":null,"article-title":"Role of phototherapy in the era of biologics.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj.h2147","key":"doi240047r24","year":"2015","issue":null,"author":"Loudon","volume":"350","first-page":"h2147","unstructured":null,"article-title":"The PRECIS-2 tool: designing trials that are fit for purpose.","journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2014.05.001","key":"doi240047r25","year":"2014","issue":"4","author":"Takeshita","volume":"71","first-page":"633","unstructured":null,"article-title":"Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.0022-202X.2005.23621.x","key":"doi240047r26","year":"2005","issue":"4","author":"Hongbo","volume":"125","first-page":"659","unstructured":null,"article-title":"Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean?","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2015.07.001","key":"doi240047r27","year":"2015","issue":"5","author":"Chiesa Fuxench","volume":"73","first-page":"868","unstructured":null,"article-title":"Validity of the Simple-Measure for Assessing Psoriasis Activity (S-MAPA) for objectively evaluating disease severity in patients with plaque psoriasis.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/jcpt.12044","key":"doi240047r28","year":"2013","issue":"2","author":"Galván-Banqueri","volume":"38","first-page":"121","unstructured":null,"article-title":"Biological treatments for moderate-to-severe psoriasis: indirect comparison.","journal-title":"J Clin Pharm Ther","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.15174","key":"doi240047r31","year":"2019","issue":"1","author":"Wan","volume":"33","first-page":"42","unstructured":null,"article-title":"Head-to-head trials of systemic psoriasis therapies: a systematic review of study design and maximum acceptable treatment differences.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj.b1542","key":"doi240047r32","year":"2009","issue":null,"author":"Koek","volume":"338","first-page":"b1542","unstructured":null,"article-title":"Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study).","journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2022.2114783","key":"doi240047r33","year":"2022","issue":"8","author":"Sevagamoorthy","volume":"33","first-page":"3086","unstructured":null,"article-title":"Racial and ethnic diversity of US participants in clinical trials for acne, atopic dermatitis, and psoriasis: a comprehensive review.","journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240047r34","year":"2023","issue":"7","author":"Sbidian","volume":"7","first-page":null,"unstructured":null,"article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":null},{"DOI":"10.1111/phpp.12349","key":"doi240047r35","year":"2017","issue":"6","author":"Click","volume":"33","first-page":"345","unstructured":null,"article-title":"Effect of availability of at-home phototherapy on the use of systemic medications for psoriasis.","journal-title":"Photodermatol Photoimmunol Photomed","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2023.2332","key":"doi240047r36","year":"2023","issue":"9","author":"Katz","volume":"159","first-page":"1006","unstructured":null,"article-title":"Home narrowband UV-B treatment for psoriasis: a cohort study.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40257-013-0015-y","key":"doi240047r37","year":"2013","issue":"2","author":"Almutawa","volume":"14","first-page":"87","unstructured":null,"article-title":"Systematic review of UV-based therapy for psoriasis.","journal-title":"Am J Clin Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240047r39","year":"2019","issue":"8","author":"Noe","volume":"18","first-page":"745","unstructured":null,"article-title":"Prescribing patterns associated with biologic therapies for psoriasis from a United States medical records database.","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1111/bjd.16776","key":"doi240047r40","year":"2019","issue":"5","author":"Warren","volume":"180","first-page":"1069","unstructured":null,"article-title":"Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.17519","key":"doi240047r41","year":"2021","issue":"11","author":"Watson","volume":"35","first-page":"2250","unstructured":null,"article-title":"The use of psoriasis biomarkers, including trajectory of clinical response, to predict clearance and remission duration to UVB phototherapy.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1177/039463200802100232","key":"doi240047r42","year":"2008","issue":"2","author":"Brazzelli","volume":"21","first-page":"481","unstructured":null,"article-title":"The duration of clinical remission of photochemotherapy and narrow-band UV-B phototherapy in the treatment of psoriasis: a retrospective study.","journal-title":"Int J Immunopathol Pharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-4632.2004.02398.x","key":"doi240047r43","year":"2006","issue":"3","author":"Boztepe","volume":"45","first-page":"245","unstructured":null,"article-title":"The effect of maintenance narrow-band ultraviolet B therapy on the duration of remission for psoriasis: a prospective randomized clinical trial.","journal-title":"Int J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1346-8138.2010.01053.x","key":"doi240047r44","year":"2011","issue":"7","author":"Karakawa","volume":"38","first-page":"655","unstructured":null,"article-title":"Duration of remission period of narrowband ultraviolet B therapy on psoriasis vulgaris.","journal-title":"J Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240047r29","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Statistical review and evaluation for BLA 761-024. US Food and Drug Administration. November 25, 2015. Accessed August 28, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761024Orig1s000StatR.pdf","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi240047r30","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Statistical review and evaluation for BLA 761042. US Food and Drug Administration. July 30, 2015. Accessed August 28, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761042Orig1s000StatR.pdf","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi240047r38","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"January 2024 DMEPOS Fee Schedule. Centers for Medicare & Medicaid Services. Updated January 1, 2024. Accessed July 31, 2024. https://www.cms.gov/medicare/payment/fee-schedules/dmepos/dmepos-fee-schedule/dme24","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2024,12,1]]},"reference-count":44,"published-online":null,"references-count":44,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":6},"unpaywall":{"doi":"10.1001/jamadermatol.2024.3897","is_oa":false,"title":"Home- vs Office-Based Narrowband UV-B Phototherapy for Patients With Psoriasis","updated":"2025-06-20T04:27:11+00:00","published_date":"2024-09-25","best_oa_location":null}},"created_at":"2025-09-20T05:48:19.207Z","updated_at":"2025-09-20T06:43:47.272Z","tags":[{"paper_doi":"10.1001/jamadermatol.2024.3897","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.3897","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.3897","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.3897","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.3897","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.3897","tag_type":"modality","value":"Narrowband UV-B Phototherapy","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.3897","tag_type":"sample_size","value":"n=783","value_numeric":783},{"paper_doi":"10.1001/jamadermatol.2024.3897","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.3897","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.3897","tag_type":"warning","value":"Indirect cost differences are described but not quantified.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.3897","tag_type":"warning","value":"Noninferiority margin is not reported in the abstract.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.3897","tag_type":"warning","value":"Open-label design may affect subjective outcomes.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.3897","tag_type":"warning","value":"The abstract does not define how adherence was measured.","value_numeric":null}],"summaries":{"what_studied":"A pragmatic, open-label, multicenter noninferiority randomized trial at 42 US dermatology practices compared 12 weeks of home narrowband UV-B with guided dosimetry vs routine office-based narrowband UV-B for plaque or guttate psoriasis in patients aged 12 years and older.","key_result":"At week 12, clear/almost clear skin (PGA ≤1) occurred in 129/393 (32.8%) with home phototherapy vs 100/390 (25.6%) with office phototherapy, and DLQI ≤5 in 206/393 (52.4%) vs 131/390 (33.6%); home phototherapy was noninferior overall and across all skin phototypes. Adherence was higher with home treatment (202/393 [51.4%] vs 62/390 [15.9%]) while persistent erythema per treatment was more frequent (466/7957 [5.9%] vs 46/3934 [1.2%]); no discontinuations occurred due to adverse events.","limitations":"Open-label pragmatic design. The abstract does not report the noninferiority margin or quantify the indirect cost differences; the adherence definition is not specified.","practice_takeaway":"Home narrowband UV-B was as effective as office-based therapy at 12 weeks, including across all skin phototypes, with higher adherence but more persistent erythema; both were well tolerated. Consider home phototherapy as an effective alternative when access or patient burden limits office-based care."}}],"initialOffset":1,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Narrowband UV-B Phototherapy"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Narrowband UV-B Phototherapy"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Narrowband UV-B Phototherapy"}}}]]

Papers